Actinium Pharmaceuticals, Inc.

ATNM · NYSE · SIC 2834: Pharmaceutical Preparations
232
SEC Filings

Business Summary

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiopharmaceutical therapeutics for oncology. Its pipeline includes ATNM-400 (non-PSMA solid tumor candidate), Actimab-A (CD33-targeted for AML/MDS and MDSC-targeting in solid tumors), Iomab-B (CD45-targeted bone marrow transplant conditioning), and Iomab-ACT (conditioning for cell and gene therapies). The company has treated over 500 patients across 15+ clinical trials and maintains an end-to-end radiopharmaceutical supply chain.

Next Earnings

Q2 FY2026 — expected 2026-08-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionATNMdiscussed_in_filing Cybersecurity
topic_mentionATNMdiscussed_in_filing Trusted Computing
topic_mentionATNMdiscussed_in_filing Blockchain & Crypto
topic_mentionATNMdiscussed_in_filing Supply Chain
topic_mentionATNMdiscussed_in_filing Regulation
topic_mentionATNMdiscussed_in_filing Healthcare & Bio
topic_mentionATNMdiscussed_in_filing Platform & Ecosystem
topic_mentionATNMdiscussed_in_filing Cybersecurity
topic_mentionATNMdiscussed_in_filing Trusted Computing
topic_mentionATNMdiscussed_in_filing Blockchain & Crypto
topic_mentionATNMdiscussed_in_filing Supply Chain
topic_mentionATNMdiscussed_in_filing Regulation
topic_mentionATNMdiscussed_in_filing Healthcare & Bio
topic_mentionATNMdiscussed_in_filing Platform & Ecosystem
topic_mentionATNMdiscussed_in_filing Cybersecurity
topic_mentionATNMdiscussed_in_filing Trusted Computing
topic_mentionATNMdiscussed_in_filing Blockchain & Crypto
topic_mentionATNMdiscussed_in_filing Supply Chain
topic_mentionATNMdiscussed_in_filing Regulation
topic_mentionATNMdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-302025-12-310001213900-26-036504EDGAR76K words
2025-03-312024-12-310001213900-25-026371EDGAR—
2024-03-292023-12-310001213900-24-028038EDGAR—
2023-03-312022-12-310001213900-23-025597EDGAR—
2022-03-252021-12-310001213900-22-015208EDGAR—
2021-03-312020-12-310001213900-21-019297EDGAR—
2020-05-082019-12-310001213900-20-011475EDGAR—
2019-03-152018-12-310001213900-19-004269EDGAR—
2018-03-162017-12-310001213900-18-003091EDGAR—
2017-03-162016-12-310001213900-17-002461EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001213900-25-110979EDGAR55K words
2025-08-082025-06-300001213900-25-073743EDGAR—
2025-05-092025-03-310001213900-25-041614EDGAR—
2024-11-142024-09-300001213900-24-098534EDGAR—
2024-08-052024-06-300001213900-24-065239EDGAR—
2024-04-262024-03-310001213900-24-036699EDGAR—
2023-11-022023-09-300001213900-23-082459EDGAR—
2023-08-142023-06-300001213900-23-067199EDGAR—
2023-05-152023-03-310001213900-23-039902EDGAR—
2022-11-142022-09-300001213900-22-072371EDGAR—
2022-08-122022-06-300001213900-22-047496EDGAR—
2022-05-132022-03-310001213900-22-026538EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-130001213900-26-016559EDGAR1K words
2025-11-260001213900-25-115586EDGAR—
2025-05-090001213900-25-041582EDGAR—
2024-11-270001213900-24-103498EDGAR—
2024-11-050001213900-24-094622EDGAR—
2024-08-050001213900-24-064993EDGAR—
2023-12-010001213900-23-092089EDGAR—
2023-03-100001213900-23-019289EDGAR—
2023-02-210001213900-23-013059EDGAR—
2022-12-300001213900-22-084094EDGAR—

232 total filings indexed. 200 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

hematologic-malignancies-(aml,-mds) solid-tumors-(prostate-cancer,-nsclc,-breast-cancer) bone-marrow-transplant-conditioning cell-and-gene-therapy-conditioning radiopharmaceutical-therapeutics alpha-emitters-(actinium-225,-lead-212) beta-emitters-(lutetium-177,-iodine-131)

Company Identity

CIK0001388320
TickerATNM
ExchangeNYSE
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: a2610c008cbb071db23d0984a441473424345b66f78839c856679d97516129b7
parent: 1f261853fe453566dd046600fb835fcc0e457cbec836d41f0fe708f1edf3169b
content hash: 396485c924cea7c98df135939fd476369990e9b70caddd074f32f739e4e0f01a
signed: 2026-04-13T04:43:47.322Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf